［1］ Yoo H J, Lim M C, Seo S S, et al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea［J］. J Gynecol Oncol, 2012,23(4): 242-250.
［2］ Paley P J, Goff B A, Minudri R, et al. The prognostic significance of radiation dose and residual tumor in the treatment of barrel-shaped endophytic cervical carcinoma ［J］. Gynecol Oncol, 2000,76（3）:373-379.
［3］ Keys H M, Bundy B N, Stehman F B, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group ［J］. Gynecol Oncol, 2003,89（3）:343-353.
［4］ Cetina L, Garcia-Arias A, Candelaria M, et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients［J］. World J Surg Oncol, 2009,7:19.
［5］ Van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review ［J］. Radiother Oncol, 2011,98（3）:287-291.
［6］ Kunos C A, Radivoyevitch T, Kresak A, et al. Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers ［J］. Int J Gynecol Cancer, 2012,22（9）:1463-1469.
［7］ Paton F, Paulden M, Saramago P, et al. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix ［J］. Health Technol Assess, 2010,14(Suppl 1):55-62.
［8］ Mossa B, Mossa S, Corosu L, et al. Follow-up in a long-term randomized trial with neoadjuvant chemotherapy for squamous cell cervical carcinoma［J］. Eur J Gynaecol Oncol, 2010,31（5）:497-503.
［9］ Sima N, Wang W, Xu Q, et al. Reversal effect of antisense RNA targeting human papillomavirus 16 (HPV16) E6E7 on malignancy of human cervical cancer cell line SiHa ［J］. Ai Zheng, 2007, 26（1）: 26-31.
［10］ Hamada K, Shirakawa T, Gotoh A, et al. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer［J］. Gynecol Oncol, 2006,103（3）: 820-830.
［11］ Wu S, Meng L, Wang S, et al. Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA ［J］. Clin Cancer Res, 2006,12（7Pt1）: 2032-2037.
［12］ 王赞宏, 李 莉, 彭芝兰, 等. 自噬基因 Beclinl 对宫颈癌 HeLa 细胞生长影响的体内外研究 ［J］. 中华肿瘤杂志, 2012, 33（11）:804-809.
［13］ Kim J, Kim B K, Lee C H, et al. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in korean women ［J］. Int J Gynecol Cancer, 2012,22（9）:1570-1576.
［14］ Su J H, Wu A, Scotney E, et al. Immunotherapy for cervical cancer: Research status and clinical potential ［J］. BioDrugs, 2010，24（2）:109-129.
［15］ Petrone L, Ammendolia M G, Cesolini A, et al. Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model ［J］. J Transl Med, 2011，9:69.
［16］ Mohit E, Bolhassani A, Zahedifard F, et al. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL/6 mouse model［J］. Scand J Immunol, 2012，75（1）:27-37.
［17］ 李 莉. LIGHT(TNFSF14)作为HPV16E7DNA疫苗佐剂在宫颈癌治疗中的作用研究［D］.武汉：华中科技大学，2011.
［18］ 高 超, 刘 颖, 蔡晓敏, 等. 白花蛇舌草对 U14 宫颈癌抗肿瘤作用的实验研究 ［J］. 实用癌症杂志, 2007，105（6）: 557-559.
［19］ 丛霄霞, 丁库克, 张 新. 中药对宫颈癌Hela细胞放射增敏作用的实验研究进展［J］.中国肿瘤, 2012,21(4): 289-291.
［20］ 李金英. 基于DC疫苗的抗原提呈探讨加减理冲汤治疗宫颈癌的实验研究［D］. 北京：北京中医药大学，2012.
(2012-02-27